Thomas A. Ban

2.6k total citations
116 papers, 1.9k citations indexed

About

Thomas A. Ban is a scholar working on Psychiatry and Mental health, Pharmacology and Clinical Psychology. According to data from OpenAlex, Thomas A. Ban has authored 116 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Psychiatry and Mental health, 29 papers in Pharmacology and 14 papers in Clinical Psychology. Recurrent topics in Thomas A. Ban's work include Schizophrenia research and treatment (29 papers), Treatment of Major Depression (25 papers) and Mental Health and Psychiatry (12 papers). Thomas A. Ban is often cited by papers focused on Schizophrenia research and treatment (29 papers), Treatment of Major Depression (25 papers) and Mental Health and Psychiatry (12 papers). Thomas A. Ban collaborates with scholars based in United States, Canada and Italy. Thomas A. Ban's co-authors include Norman Sartorius, William Guy, William H. Wilson, H. E. Lehmann, Mitchell B. Balter, E. H. Uhlenhuth, Kenneth C. C. Yang, William M. Petrie, William H. Wilson and W. Horsley Gantt and has published in prestigious journals such as American Journal of Psychiatry, Trends in Neurosciences and The British Journal of Psychiatry.

In The Last Decade

Thomas A. Ban

112 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas A. Ban United States 20 743 390 355 353 236 116 1.9k
Frank J. Ayd United States 21 1.0k 1.4× 499 1.3× 169 0.5× 375 1.1× 250 1.1× 101 2.5k
Matthias J. Müller Germany 28 1.0k 1.4× 304 0.8× 322 0.9× 368 1.0× 142 0.6× 61 1.9k
Ronald R. Fieve United States 33 1.9k 2.6× 722 1.9× 420 1.2× 427 1.2× 284 1.2× 92 3.1k
J. Ananth Canada 20 736 1.0× 328 0.8× 159 0.4× 262 0.7× 260 1.1× 92 1.8k
Y.D. Lapierre Canada 27 1.1k 1.5× 521 1.3× 432 1.2× 560 1.6× 347 1.5× 139 2.6k
Max Schmauß Germany 21 836 1.1× 423 1.1× 326 0.9× 350 1.0× 355 1.5× 101 2.3k
H. E. Lehmann Canada 22 601 0.8× 223 0.6× 169 0.5× 305 0.9× 122 0.5× 100 1.5k
L Annable Canada 33 1.6k 2.1× 655 1.7× 568 1.6× 420 1.2× 235 1.0× 93 3.0k
F. A. Jenner United Kingdom 25 533 0.7× 181 0.5× 215 0.6× 161 0.5× 300 1.3× 92 1.9k
Rosa Catalán Spain 28 952 1.3× 582 1.5× 437 1.2× 315 0.9× 565 2.4× 157 2.8k

Countries citing papers authored by Thomas A. Ban

Since Specialization
Citations

This map shows the geographic impact of Thomas A. Ban's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Ban with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Ban more than expected).

Fields of papers citing papers by Thomas A. Ban

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Ban. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Ban. The network helps show where Thomas A. Ban may publish in the future.

Co-authorship network of co-authors of Thomas A. Ban

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Ban. A scholar is included among the top collaborators of Thomas A. Ban based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Ban. Thomas A. Ban is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ban, Thomas A.. (2006). In memory of three pioneers. The International Journal of Neuropsychopharmacology. 9(4). 475–475. 6 indexed citations
2.
Ban, Thomas A.. (2006). Academic psychiatry and the pharmaceutical industry. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 30(3). 429–441. 19 indexed citations
3.
Ban, Thomas A.. (2004). Neuropsychopharmacology and the genetics of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 28(5). 753–762. 17 indexed citations
4.
Ban, Thomas A.. (2001). Pharmacotherapy of mental illness - a historical analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 25(4). 709–727. 63 indexed citations
5.
Ban, Thomas A.. (2000). Nosology in the teaching of psychiatry. Jornal Brasileiro de Psiquiatria. 49(3). 39–49. 2 indexed citations
6.
Ban, Thomas A.. (1999). Selective drugs versus heterogeneous diagnoses towards a new methodology in psychopharmacologic research. Psiquiatría Biológica. 7(4). 177–189. 6 indexed citations
7.
Uhlenhuth, E. H., Mitchell B. Balter, Thomas A. Ban, & Kenneth C. C. Yang. (1999). International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depression and Anxiety. 9(3). 107–116. 48 indexed citations
8.
Uhlenhuth, E. H., Mitchell B. Balter, Thomas A. Ban, & Kenneth C. C. Yang. (1999). International Study of Expert Judgment on Therapeutic Use of Benzodiazepines and Other Psychotherapeutic Medications: IV. Therapeutic Dose Dependence and Abuse Liability of Benzodiazepines in the Long-Term Treatment of Anxiety Disorders. Journal of Clinical Psychopharmacology. 19(6 Suppl 2). 23S–29S. 49 indexed citations
9.
Ban, Thomas A.. (1995). Psychopharmacology and successful cerebral aging. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 19(1). 1–9. 8 indexed citations
10.
Parnetti, Lucilla, Thomas A. Ban, & Umberto Senin. (1995). Glycosaminoglycan Polysulfate in Primary Degenerative Dementia. Neuropsychobiology. 31(2). 76–80. 1 indexed citations
11.
Ban, Thomas A., Leslie C. Morey, F. Rengo, et al.. (1992). Early manifestations of dementing illness: Treatment with glycosaminoglycan polysulfate. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 16(5). 661–676. 7 indexed citations
12.
Ban, Thomas A., Leslie C. Morey, Eugenio Aguglia, et al.. (1991). Glycosaminoglycan polysulfate in the treatment of old age dementias. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 15(3). 323–342. 6 indexed citations
13.
Ban, Thomas A., Leslie C. Morey, Eugenio Aguglia, et al.. (1990). Nimodipine in the treatment of old age dementias. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 14(4). 525–551. 64 indexed citations
14.
Ban, Thomas A.. (1990). Clinical Pharmacology and Leonhard’s Classification of Endogenous Psychoses. Psychopathology. 23(4-6). 331–338. 12 indexed citations
15.
Ban, Thomas A., et al.. (1989). Diagnosis and treatment of old age dementias. KARGER eBooks. 9 indexed citations
16.
Ban, Thomas A.. (1983). Age and the pharmacology of psychoactive drugs. Trends in Neurosciences. 6. 71–71. 3 indexed citations
17.
Ban, Thomas A., et al.. (1979). Identification of high-risk criteria in the framework of W.H.O. collaborative research in the major mental disorders. Progress in Neuro-Psychopharmacology. 3(5-6). 575–578. 1 indexed citations
18.
Ban, Thomas A.. (1974). Negative Findings with Nicotinic Acid in the Treatment ofSchizophrenias. International Pharmacopsychiatry. 9(3). 172–187. 7 indexed citations
19.
Ban, Thomas A.. (1971). Drug Treatment in Schizophrenia . Canadian Psychiatric Association Journal. 16(6). 473–485. 29 indexed citations
20.
Ban, Thomas A. & W. Horsley Gantt. (1964). Conditioning and psychiatry. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frank J. Ayd Breakdown of academic impact, for papers by Matthias J. Müller Breakdown of academic impact, for papers by Ronald R. Fieve Breakdown of academic impact, for papers by J. Ananth Breakdown of academic impact, for papers by Y.D. Lapierre Breakdown of academic impact, for papers by Max Schmauß Breakdown of academic impact, for papers by H. E. Lehmann Breakdown of academic impact, for papers by L Annable Breakdown of academic impact, for papers by F. A. Jenner Breakdown of academic impact, for papers by Rosa Catalán
Rankless by CCL
2026